Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia

Table S1. Sensitivity values used in the model

Organism	Ceftolozane/ tazobactam	Cefepime	Ceftazidime	Ciprofloxacin	Doripenem	Imipenem	Levofloxacin	Meropenem	Piperacillin/ tazobactam
Acinetobacter baumannii	14.04%	15.79%	15.79%	15.79%	15.79%	15.79%	15.79%	15.79%	10.53%
Citrobacter freundii	60.00%	100.00%	60.00%	100.00%	100.00%	100.00%	100.00%	100.00%	40.00%
Citrobacter koseri	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Enterobacter aerogenes	100.00%	83.33%	83.33%	100.00%	100.00%	100.00%	100.00%	100.00%	66.67%
Enterobacter cloacae	79.55%	47.73%	59.09%	59.09%	95.45%	95.45%	81.82%	95.45%	59.09%
Escherichia coli	97.66%	72.51%	77.19%	60.82%	100.00%	100.00%	62.57%	100.00%	88.89%
Haemophilus influenzae	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%
Klebsiella oxytoca	100.00%	100.00%	100.00%	87.50%	100.00%	100.00%	87.50%	100.00%	87.50%
Klebsiella pneumoniae	59.62%	44.23%	44.23%	40.38%	72.44%	73.72%	49.36%	69.23%	41.67%
Morganella morganii	100.00%	100.00%	93.33%	80.00%	100.00%	26.67%	86.67%	100.00%	100.00%
Proteus mirabilis	100.00%	82.61%	100.00%	65.22%	100.00%	47.83%	73.91%	100.00%	100.00%
Pseudomonas aeruginosa	92.92%	81.42%	81.42%	76.99%	73.45%	74.34%	75.22%	76.99%	82.30%
Serratia marcescens	90.32%	87.10%	83.87%	0.00%	90.32%	93.55%	0.00%	93.55%	0.00%
Stenotrophomonas maltophilia	14.29%	0.00%	14.29%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%



Figure S1. Univariate sensitivity analysis results for ceftolozane/tazobactam and cefepime comparison in cUTI



Figure S2. Univariate sensitivity analysis results for ceftolozane/tazobactam and ceftazidime comparison in cUTI



Figure S3. Univariate sensitivity analysis results for ceftolozane/tazobactam and ciprofloxacin comparison in cUTI



Figure S4. Univariate sensitivity analysis results for ceftolozane/tazobactam and doripenem comparison in cUTI



Figure S5. Univariate sensitivity analysis results for ceftolozane/tazobactam and imipenem/cilastatin comparison in cUTI



Figure S6. Univariate sensitivity analysis results for ceftolozane/tazobactam and levofloxacin comparison in cUTI



Figure S7. Univariate sensitivity analysis results for ceftolozane/tazobactam and meropenem comparison in cUTI



Figure S8. Univariate sensitivity analysis results for ceftolozane/tazobactam and piperacillin/tazobactam comparison in cUTI



Figure S9. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and cefepime + metronidazole comparison in cIAI



Figure S10. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and ceftazidime + metronidazole comparison in cIAI



Figure S11. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and ciprofloxacin + metronidazole comparison in cIAI



Figure S12. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and doripenem comparison in cIAI



Figure S13. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and imipenem/cilastatin comparison in cIAI



Figure S14. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and levofloxacin + metronidazole comparison in cIAI



Figure S15. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and meropenem comparison in cIAI



Figure S16. Univariate sensitivity analysis results for ceftolozane/tazobactam + metronidazole and piperacillin/tazobactam comparison in cIAI



Figure S17. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and cefepime + metronidazole comparison in cIAI



Figure S18. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and ceftazidime + metronidazole comparison in cIAI



Figure S19. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and ciprofloxacin + metronidazole comparison in cIAI



Figure S20. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and doripenem comparison in cIAI



Figure S21. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and imipenem/cilastatin comparison in cIAI



Figure S22. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and levofloxacin + metronidazole comparison in cIAI



Figure S23. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and meropenem comparison in cIAI



Figure S24. Probabilistic sensitivity analysis results for ceftolozane/tazobactam + metronidazole and piperacillin/tazobactam comparison in cIAI



Figure S25. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and cefepime comparison in cUTI



Figure S26. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and ceftazidime comparison in cUTI



Figure S27. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and ciprofloxacin comparison in cUTI



Figure S28. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and doripenem comparison in cUTI



Figure S29. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and imipenem/cilastatin comparison in cUTI



Figure S30. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and levofloxacin comparison in cUTI



Figure S31. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and meropenem comparison in cUTI



Figure S32. Probabilistic sensitivity analysis results for ceftolozane/tazobactam and piperacillin/tazobactam comparison in cUTI